补中益气颗粒联合多糖铁复合物治疗妊娠期缺铁性贫血疗效和安全性分析

目的:探讨补中益气颗粒联合多糖铁复合物治疗妊娠期缺铁性贫血(IDA)的临床疗效。方法:将120例妊娠期IDA患者按照随机数字表法分为2组,每组60例。对照组给予多糖铁复合物治疗,研究组给予补中益气颗粒联合多糖铁复合物治疗,均用药4周。比较2组治疗前后红细胞(RBC)计数、血红蛋白(Hb)含量、平均红细胞血红蛋白含量(MCH)、血清铁(SI)、血清铁蛋白(SF)、铁调素和可溶性转铁蛋白受体(sTfR),以及2组治疗总有效率、不良反应和不良妊娠结局发生率。结果:治疗后研究组RBC、Hb、MCH、SI和SF均高于对照组,铁调素和sTfR低于对照组,治疗总有效率高于对照组,差异均有统计学意义(均P0.05)。2组不良反应发生率和不良妊娠结局发生率差异无统计学意义(P0.05)。结论:补中益气颗粒联合多糖铁复合物可有效改善铁代谢,治疗妊娠期IDA效果显著,安全性较好。     

多糖铁复合物治疗成年女性缺铁性贫血疗效分析

目的 探讨多糖铁复合物治疗成年女性缺铁性贫血的临床效果。方法 选择2018年1月-2020年12月在本院治疗的82例成年女性缺铁性贫血患者作为研究对象,41例接受琥珀酸亚铁片治疗作为对照组,41例接受多糖铁复合物治疗作为观察组,比较两组患者治疗后4周疗效与胃肠道不良反应发生率的差异。结果 观察组与对照组治疗前Hb、RBC、SF、MCV指标差异均无统计学意义（P>0.05）;观察组与对照组治疗后4周Hb、RBC、SF、MCV指标均较治疗前有所改善,差异程度均有统计学意义（P<0.05）;观察组与对照组治疗后Hb、RBC、SF、MCV指标差异均无统计学意义（P>0.05）。观察组治疗有效率为95.12%,高于对照组92.69%,但差异无统计学意义（P>0.05）。观察组胃肠道不良反应发生率为2.44%,低于对照组19.51%,差异有统计学意义（P<0.05）。结论 多糖铁复合物治疗成年女性缺铁性贫血有效,胃肠道不良反应发生率低。     

多糖铁复合物治疗小儿缺铁性贫血临床观察

小儿缺铁性贫血(IDA)是常见的营养缺乏性疾病,我国儿童贫血的发病率高达37．9％,其中多数为IDA。小儿正处于生长发育加速期,单纯通过膳食摄取铁剂不能纠正贫血,及时予以铁剂治疗十分重要。我院应用多糖铁复合物(PIC)治疗IDA患儿 37例,取得一定效果。一、资料与方法 1．病历选择以6岁以下小儿,血红蛋白< 110g/L;6岁-14岁小儿,血红蛋白<120g／L作为小     

妊娠期孕妇缺铁性贫血的预防与治疗

世界卫生组织资料显示,发展中国家患有贫血的孕妇占50%。中国是最大的发展中国家,贫血在孕妇中非常常见。常见种类主要有缺铁性贫血和巨幼红细胞贫血。据报告,我国孕妇贫血患病率为40%,以缺铁性贫血为主,占70%。因为在妊娠中后期,胎儿生长发育和妊娠期血容量增加对铁的需要量也在急剧增加,孕妇对铁摄取不足或吸收不良,很容易发生缺铁性     

妊娠期铁缺乏和缺铁性贫血的影响因素分析

目的 调查研究妊娠期铁缺乏(ID)及缺铁性贫血(IDA)的检出率、治疗状况及其影响因素.方法 选取2019年9～11月于厦门大学附属妇女儿童医院产检的妊娠中、晚期孕妇400例,收集病史,检查血红蛋白和血清铁蛋白等指标.结果 调查对象的血清铁蛋白中位数为18.6 μg/I.,血红蛋白中位数为115.0 g/I.,其中妊娠...     

多糖铁复合物(PIC)用于妊娠缺铁性贫血的疗效观察

目的:评价多糖铁复合物(PIC)(商品名:力蜚能)用于妊娠合并缺铁性贫血的疗效及其耐受性。方法:将妊娠合并缺铁性贫血的妇女随机分为实验组(口服力蜚能150 mg/次,2次/日)和对照组(口服硫酸亚铁0.3g/次,3次/日)。治疗4周后复查血红细胞计数、血红蛋白、血球压积、网织红细胞、血清铁及转铁蛋白,并进行疗效判断。结果:治疗组有效率为90.3%,对照组率有效率为84.8%,差异显著(P<0.05),且未见副作用。结论:力蜚能治疗妊娠缺铁性贫血效果好,无明显不良反应。     

多糖铁复合物治疗缺铁性贫血的疗效及对sTfR和SF含量的影响

目的研究探讨多糖铁复合物治疗缺铁性贫血的疗效以及其对血清转铁蛋白受体(s TfR)和血清铁蛋白(SF)的影响。方法选取我院收治的缺铁性贫血患者180例作为研究对象,将其随机分为两组,每组90例,对照组患者给予硫酸亚铁颗粒口服,观察组患者给予多糖铁复合物胶囊口服,治疗时长为8周。比较两组患者治疗前后的s TfR及SF的变化情况,并观察治疗结束之后两组患者的临床治疗效果。结果用药之后两组患者各项指标均有显著改善,与治疗前相比有统计学差异(p<0.05),两组患者治疗后Hb和RBC的比较也有统计学差异(p<0.05),但s TfR和SF相差不大,无统计学差异(p>0.05)。观察组患者和对照组患者的治疗有效率分别为97.8%和86.7%,比较有显著差异(p<0.05),具有统计学意义。结论多糖复合铁剂虽然在治疗缺铁性贫血中不能通过SF和s TfR来表达其优越性,但是能显著改善缺铁性贫血患者的临床症状,治疗的有效率高。说明多糖铁复合物是理想的治疗缺铁性贫血的药物,值得临床推广应用。     

452例孕妇缺铁性贫血分析

目的调查了解孕妇缺铁性贫血与孕周关系及影响贫血发生的因素,提出预防措施。方法对850例孕妇进行血红蛋白(Hb)、血清铁(Fe)测定。结果妊娠缺铁性贫血的发生率为53%,随着孕周的进展贫血发生率增高,孕28周后贫血发生率上升显著,孕28周~36周时贫血发生率最高达53%。结论建议对孕妇的补铁可从孕12周~16周后开始。     

妊娠期亚临床甲状腺功能减退症与贫血的相关性研究

目的：探讨妊娠期亚临床甲状腺功能减退症（SCH）与贫血之间的关系及治疗是否能改善妊娠期贫血的发生率。方法：选择SCH孕妇1 087例为SCH组;甲状腺功能正常孕妇4 942例为对照组（均排除妊娠早期贫血）。SCH组按是否愿接受药物治疗,分为SCH-治疗组和SCH-未治组,比较SCH组与对照组的甲状腺过氧化物酶抗体（TPOAb）阳性率,根据妊娠晚期血常规检查结果,比较各组的贫血发生率。结果：①SCH组的TPOAb阳性率高于对照组,差异有统计学意义（23.4% vs. 9.4%, χ2=163.920,P=0.000）。②妊娠晚期SCH组贫血发生率高于对照组,差异有统计学意义（25.4% vs. 21.0%, χ2=9.459,P=0.002）。SCH-治疗组的贫血发生率低于SCH-未治组,但差异无统计学意义（22.9% vs. 26.5%,P=0.204）。结论：SCH会增加孕妇妊娠晚期贫血的发病风险,给予左旋甲状腺激素（LT4）有利于降低SCH孕妇的贫血发生率。     

孕妇缺铁性贫血影响因素分析

目的探讨孕妇孕期缺铁性贫血的影响因素。方法对进行产前检查的早孕孕妇,按血色素和血清铁蛋白分为缺铁性贫血组35名和对照组104名进行问卷调查。所得资料运用t检验、χ2检验和U检验进行分析。结果两组孕妇在体重、BMI指数、早孕反应、偏食情况、孕期补铁食物摄入频次、生产方式等方面差异有统计学意义(P<0·05,或P<0·01)。结论育龄期饮食结构不合理是导致孕期缺铁性贫血发生的重要因素。     

一种新型补铁剂改善大鼠营养性贫血研究

[目的]考察多糖铁复合物对营养性贫血大鼠的疗效,为多糖铁的开发应用提供理论依据。[方法]采用给予低铁饲料结合定期少量放血的方法建立缺铁性贫血大鼠模型,检测给药前后血红蛋白及红细胞内游离原卟啉含量。[结果]25、50、150 mg/kg·bw剂量组动物的血红蛋白含量,501、50 mg/kg·bw剂量组动物的红细胞内游离原卟啉含量与低铁对照组比较均有统计学意义（P〈0.01）,效果优于阳性对照组。[结论]多糖铁胶囊具有良好的改善营养性贫血的作用。     

宜昌市夷陵区妊娠期妇女贫血相关知信行调查分析

目的 了解妊娠期妇女对妊娠期贫血的知信行状况.方法 以宜昌市夷陵区妇幼保健院管理的妊娠期妇女为研究对象,通过对其妊娠期贫血防治相关知识、态度和行为的调查,了解妊娠期妇女的贫血相关知信行现状.结果 妊娠期妇女对于贫血防治的态度较为积极,但对妊娠贫血的诊断标准、常见症状、贫血的危害等知识的知晓率较低.经多元Logistic回归分析显示,是否知晓贫血标准（OR=4.76,95％CI=2.00～11.32）、是否知晓妊娠期应该补铁（OR=3.01,95％CI=2.00～4.52）,以及是否愿意了解预防贫血的知识（OR=7.81,95％CI=1.03～59.23）等是影响妊娠期妇女采取有效防治行为的主要因素.此外,不同妊娠周期的孕妇获取妊娠贫血知识的途径差异不大.结论 妊娠期妇女掌握正确的妊娠期贫血防治知识和采取防治措施的比例较低,需有针对性地加强当地妊娠贫血防治工作.     

初次妊娠孕妇妊娠期缺铁性贫血及贫血程度的影响因素分析

目的 探讨初次妊娠孕妇妊娠期缺铁性贫血及贫血程度的影响因素.方法 回顾性分析2016年1月至2019年12月我院收治的980例初次妊娠孕妇的临床资料,依据是否出现缺铁性贫血分为对照组(未出现缺铁性贫血,800例)和观察组(出现缺铁性贫血,180例).根据病情严重程度将观察组分为轻度组(血红蛋白100～ 109 g/L,...     

Comparison of Two Doses of Elemental Iron in the Treatment of Latent Iron Deficiency: Efficacy,Side Effects and Blinding Capabilities

Adherence to iron supplementation can be compromised due to side effects, and these limit blinding in studies of iron deficiency. No studies have reported an efficacious iron dose that allows participants to remain blinded. This pilot study aimed to determine a ferrous sulfate dose that improves iron stores, while minimising side effects and enabling blinding. A double-blinded RCT was conducted in 32 women (18–35 years): 24 with latent iron deficiency (serum ferritin < 20 µg/L) and 8 iron sufficient controls. Participants with latent iron deficiency were randomised to 60 mg or 80 mg elemental iron or to placebo, for 16 weeks. The iron sufficient control group took placebo. Treatment groups (60 mg n = 7 and 80 mg n = 6) had significantly higher ferritin change scores than placebo groups (iron deficient n = 5 and iron sufficient n = 6), F(1, 23) = 8.46, p ≤ 0.01. Of the 24 who completed the trial, 10 participants (77%) on iron reported side effects, compared with 5 (45%) on placebo, but there were no differences in side effects (p = 0.29), or compliance (p = 0.60) between iron groups. Nine (69%) participants on iron, and 11 (56%) on placebo correctly guessed their treatment allocation. Both iron doses were equally effective in normalising ferritin levels. Although reported side-effects were similar for both groups, a majority of participants correctly guessed their treatment group.     

Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment

Iron deficiency anemia (IDA) is a common manifestation of Inflammatory Bowel Disease (IBD). Oral iron supplements are the treatment of choice, but are not always well tolerated. Sucrosomial^® iron (SI) may represent an alternative. This prospective study assessed the tolerability and effectiveness of SI, and quality of life (QoL) of IDA-IBD patients who were intolerant to oral iron salts. The study included 52 individuals treated with 1 capsule/day for 12 weeks. Tolerability was assessed through a gastrointestinal symptom severity questionnaire. Hemoglobin (Hb) levels and clinical symptoms of IDA were analyzed. QoL was assessed using IBDQ-9 and EuroQoL questionnaires. The percentage of patients with excellent/good health increased from 42.9% to 94.3%. Mean Hb concentration significantly increased at all follow-up visits (p < 0.05). Almost all participants (96.9%) were adherent to the study medication. Patients’ QoL improved (IBDQ-9: from 60.9 to 65.5). Patients also improved in mobility (71.8% to 78.1%), usual activities (51.3% to 68.7%), pain/discomfort (41.0% to 53.1%), and extreme depression/anxiety problems (7.7% to 3.2%); they worsened in self-care (100% to 90.6%), but perceived an enhancement in their global health [EQ-VAS score: 61.9 (±26.1) to 66.9 (±20.3)]. SI was well tolerated and improved IDA symptoms, IBD activity, and patients’ QoL. In conclusion, SI should be considered in IDA–IBD patients.     

短期碘铁联合缺乏大鼠动物模型的建立

目的通过饮食控制碘铁摄入量,建立碘铁联合缺乏的大鼠动物模型。方法选择健康SPF/VAF级初断乳SD雄性大鼠22只,按体重随机分为对照组(饲以改良的AOAC饲料,碘含量为280μg/kg,铁含量为50mg/kg),缺碘缺铁组(饲以改良的AOAC缺碘缺铁饲料,碘含量为66μg/kg,铁含量为15mg/kg),每组11只。饲养4周后,测定体重和甲状腺重量,并计算甲状腺系数。测定大鼠尿碘、血清甲状腺激素、血红蛋白、血清铁水平和总铁结合力。结果缺碘缺铁组大鼠皮肤苍白,皮毛粗糙稀疏。与对照组比较,缺碘缺铁组大鼠体重、尿碘、血红蛋白、血清铁、血清游离三碘甲腺原氨酸(fT3)、游离甲状腺素(fT4)水平均较低,甲状腺重量及其脏器系数、总铁结合力和fT3/fT4比值均较高,差异有统计学意义(P0.05);促甲状腺激素(TSH)水平有升高趋势,但差异无统计学意义。结论该模型同时具有碘缺乏和铁缺乏特征,通过饮食控制大鼠碘铁摄入量成功制备碘铁联合缺乏大鼠动物模型。     

Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized,Controlled Trial

Iron deficiency in pregnancy is a major public health problem that causes maternal complications. The objective of this randomized, controlled trial was to examine the bioavailability, efficacy, and safety of oral ferrous bisglycinate plus folinic acid supplementation in pregnant women with iron deficiency. Subjects (12–16 weeks of gestation, n = 120) were randomly allocated to receive oral iron as ferrous bisglycinate (equiv. iron 24 mg) in supplement form with folinic acid and multivitamins (test group, n = 60) or as ferrous fumarate (equiv. iron 66 mg iron, control group, n = 60) after breakfast daily. Iron absorption was assessed by measuring fasted serum iron levels at 1 and 2 h immediately after supplementation. Hematological biomarkers and iron status were assessed before intervention, and at 3 and 6 months. Side effects were monitored throughout the intervention. A significant increase in serum iron was seen in both groups (p < 0.001) during the bioavailability assessment; however, the test group increases were comparatively higher than the control values at each timepoint (p < 0.001). Similarly, both test and control groups demonstrated a statistically significant increases in hemoglobin (Hb) (p < 0.001), erythrocytes (p < 0.001), reticulocytes (p < 0.001), mean corpuscular volume (MCV) (p < 0.001), mean corpuscular hemoglobin (MCH) (p < 0.001), mean corpuscular hemoglobin concentration (MCHC) (p < 0.001), % transferrin saturation (p < 0.001), and ferritin (p < 0.001) at 3 and 6 months after supplementation. However, in all cases, the test group increases were numerically larger than the control group increases at each timepoint. The test intervention was also associated with significantly fewer reports of nausea, abdominal pain, bloating, constipation, or metallic taste (p < 0.001). In conclusion, ferrous bisglycinate with folinic acid as a multivitamin nutraceutical format is comparable to standard ferrous fumarate for the clinical management of iron deficiency during pregnancy, with comparatively better absorption, tolerability, and efficacy and with a lower elemental iron dosage.     

多巴丝肼联合普拉克索治疗帕金森的临床疗效及安全性分析

目的探析多巴丝肼联合普拉克索治疗帕金森的临床疗效及安全性,旨在为今后临床用药提供参考依据。方法前瞻性选择我院2015年5月—2016年5月期间收治的60例帕金森病患者为研究对象,采用随机数字表法分为2组,每组各30例;对照组给予多巴丝肼治疗,治疗组给予多巴丝肼联合普拉克索治疗;观察两组患者临床疗效及UPDRS评分。结果治疗组总有效率为93.34%,明显高于对照组的73.33%(P<0.05);经治疗后,两组患者UPDRS评分较治疗前明显降低(P<0.05),且治疗组UPDRS评分较对照组降低程度更低(P<0.05);治疗组不良反应率为13.33%,明显低于对照组的40.00%(P<0.05)。结论多巴丝肼联合普拉克索治疗帕金森的临床疗效显著,安全性高,值得临床应用与推广。